#SHKhelkar conducted their conference call today at 2:00 PM
"Expected to continue the momentum (~15% growth) and improve the margins"
Here are the key takeaways π
Business Updates:
β’ All the segment grew well. Acquired new customer in the domestic market.
β’ Net debt reduce by 132cr owing to increase in CF.
β’ Did the acquisition of Nova in this quarter.
β’ Co. focus on improving the Cash Flow generation and strengthening Balance Sheet.
Domestic Market (Covid)
β’ All the domestic segment grew well, and there was no impact on customer side in domestic market.
β’ Covid did had little impact over the segment, however growth momentum again picked up.
β’ Expected to growth 12-13% over coming year.
Fragrance Segment:
β’ Won some few mid and large size FMCG.
β’ Improving operating leverage resulted in higher profitability YoY basis.
β’ Domestic market has grown well, Europe remain major contributor of growth.
Flavour Market:
β’ Flavour market is expected to grow more than Fragrance market.
β’ Target remains 17-18% growth.
β’ Domestic and Europe market grew well in Q4.
+
Nova Fragranze:
β’ SH has some internal sales, while incremental sales of the company stands around 10-12cr.
β’ Nova shares relatively higher margins and growth is expected to come in coming year.
β’ Effective from this quarter.
Write off:
β’ There are certain project which didn't worked well for the company, which has been written off.
β’ While there certain other new project, SH is working on increasing the CWIP.
β’ Certain write off expense will be carried to next year.
CFF Segment:
β’ CFF segment grew at around 7-8% and is expected to grow well in Italy market.
β’ Target remains 9-10% growth over coming years (including Nova sales)
Future Focus:
β’ Company has done enough capex in past and now focus remains on increasing the growth of company.
β’ With increasing volume margins is expected to be improve. Gross Margins target of 45% over next 5 year.
β’ R&D expense will increase as increase in margin.
Isobionics:
β’ Sandalwood oil is unique product. Typically trees take 15-16 years and there is risk of bio-diversity.
β’ With this SH has tied up with Santalol, which is made other organic product.
β’ Guideline: 25 cr with 10% margin, and 7-8% net margin.
Debt:
β’ In coming 2-3 years co. would be looking much on becoming debt free. However target remains to generate enough CF to be net debt positive.
β’ If co. dont find any good good acquisition, then there would be focus on reducing the debt.
β’ Much of the debt is at lower rate.
For more discussion on Equity research and OI analysis
Alkyl Amines conducted their conference call today at 4 pm.
Here are the key takeaways π
Business Updates:
β’ Much of growth contributors was value growth.
β’ Around 1/3 growth delivered by volume and 2/3 in volume. There were certain supply chin issue, leading to lower growth ion volume.
Growth:
β’ Co. is fairly optimistic on volume, with respect to sales in Pharma, as Pharma is going well.
β’ 3-5 year Volume growth target: 15%+ CAGR.
β’ There can be mid blip due to expansion.
#Cadila Healthcare conducted their conference call yesterday for Q4 FY2021
"Cadila is 2nd larget growing company in Pharma space"
Here are the key takeaways π
Business Updates:
β’ India business grew 20% (includes human health, consumer wellness, & animal wellness)- 16.4BilRs.
β’ US (generic and Sepciality)- 16.03Bill Rs. QoQ decline
β’ Emerging Market growth- 11%: 2.93BilRs Sales.
β’ Launched 7 new product and approvals of 9 product.
Revenue Mix:
β’ Human Health (India)- 21% growth (YoY).- 11.04BilRs
β’ Branded Generic Business grew 24% YoY
β’ Gained market share in Pain Mgmt, Anti-Effective, Anti-Diabetic.
β’ Market Share in Gyno, Pain Mgmt, Respiratory was maintained.
β’ Animal Health- 17% growth.
IG Petrochemicals Ltd. Conducted their conference call today at 3:30 pm.
" To become a well diversified chemical company with leadership in PAN* Industry. "
Here are the key takeaways π...
Business Overview
- Company has given robust growth in both QoQ and YoY basis.
- They still maintain their position of being the largest manufacturer of phthalic Anhydride (PAN) and maleic anhydride.(MAN)
- With government demand being bullish on downstream products like Paints, Plasticizers, UPR and all , there will be demand of PAN in domestic markets.
- They have a positive correlation with the infrastructure industry leading to a strong demand growth.
Balaji Amines conducted their Conference Call today at 4:00 pm.
Here are the key takeaways π
Business Updates:
β’ EBIDTA growth- 78% Driver were increasing demand and improving price realization.
β’ Zero debt co. on standalone basis.
β’ Certain product are now exported to China.
Ethylamines:
β’ With implementation of new technology the cost of production is expected to lower.
β’ Demand is India is expected to increase by 12-15% over years.
β’ Import of Ethylamines is 9,000 Tones in India.
β’ Majority will be sell directly in market.